Literature DB >> 21543337

Regulation of Src family kinases involved in T cell receptor signaling by protein-tyrosine phosphatase CD148.

Ondrej Stepanek1, Tomas Kalina, Peter Draber, Tereza Skopcova, Karel Svojgr, Pavla Angelisova, Vaclav Horejsi, Arthur Weiss, Tomas Brdicka.   

Abstract

CD148 is a receptor-like protein-tyrosine phosphatase known to inhibit transduction of mitogenic signals in non-hematopoietic cells. Similarly, in the hematopoietic lineage, CD148 inhibited signal transduction downstream of T cell receptor. However, it also augmented immunoreceptor signaling in B cells and macrophages via dephosphorylating C-terminal tyrosine of Src family kinases (SFK). Accordingly, endogenous CD148 compensated for the loss of the main SFK activator CD45 in murine B cells and macrophages but not in T cells. Hypothetical explanations for the difference between T cells and other leukocyte lineages include the inability of CD148 to dephosphorylate a specific set of SFKs involved in T cell activation or the lack of CD148 expression during critical stages of T cell development. Here we describe striking differences in CD148 expression between human and murine thymocyte subsets, the only unifying feature being the absence of CD148 during the positive selection when the major developmental block occurs under CD45 deficiency. Moreover, we demonstrate that similar to CD45, CD148 has both activating and inhibitory effects on the SFKs involved in TCR signaling. However, in the absence of CD45, activating effects prevail, resulting in functional complementation of CD45 deficiency in human T cell lines. Importantly, this is independent of the tyrosines in the CD148 C-terminal tail, contradicting the recently proposed phosphotyrosine displacement model as a mechanism of SFK activation by CD148. Collectively, our data suggest that differential effects of CD148 in T cells and other leukocyte subsets cannot be explained by the CD148 inability to activate T cell SFKs but rather by its dual inhibitory/activatory function and specific expression pattern.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21543337      PMCID: PMC3121354          DOI: 10.1074/jbc.M110.196733

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  CD148: a receptor-type protein tyrosine phosphatase involved in the regulation of human T cell activation.

Authors:  S G Tangye; J H Phillips; L L Lanier; J E de Vries; G Aversa
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

2.  Negative regulation of human T cell activation by the receptor-type protein tyrosine phosphatase CD148.

Authors:  S G Tangye; J Wu; G Aversa; J E de Vries; L L Lanier; J H Phillips
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

3.  Molecular cloning, characterization, and chromosomal localization of a novel protein-tyrosine phosphatase, HPTP eta.

Authors:  H Honda; J Inazawa; J Nishida; Y Yazaki; H Hirai
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

4.  CD148, a membrane protein tyrosine phosphatase, is able to induce tyrosine phosphorylation on human lymphocytes.

Authors:  E Palou; M A de la Fuente-García; J M Nicolás; C Vilardell; J Vives; A Gayá
Journal:  Immunol Lett       Date:  1997-06-01       Impact factor: 3.685

5.  Severe combined immunodeficiency with abnormalities in expression of the common leucocyte antigen, CD45.

Authors:  C M Cale; N J Klein; V Novelli; P Veys; A M Jones; G Morgan
Journal:  Arch Dis Child       Date:  1997-02       Impact factor: 3.791

6.  Thyroid cell transformation inhibits the expression of a novel rat protein tyrosine phosphatase.

Authors:  L Zhang; M L Martelli; C Battaglia; F Trapasso; D Tramontano; G Viglietto; A Porcellini; M Santoro; A Fusco
Journal:  Exp Cell Res       Date:  1997-08-25       Impact factor: 3.905

7.  CD148 is a membrane protein tyrosine phosphatase present in all hematopoietic lineages and is involved in signal transduction on lymphocytes.

Authors:  M A de la Fuente-García; J M Nicolás; J H Freed; E Palou; A P Thomas; R Vilella; J Vives; A Gayá
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

8.  The Syk protein tyrosine kinase can function independently of CD45 or Lck in T cell antigen receptor signaling.

Authors:  D H Chu; H Spits; J F Peyron; R B Rowley; J B Bolen; A Weiss
Journal:  EMBO J       Date:  1996-11-15       Impact factor: 11.598

9.  Molecular cloning and characterization of Byp, a murine receptor-type tyrosine phosphatase similar to human DEP-1.

Authors:  S Kuramochi; S Matsuda; Y Matsuda; T Saitoh; M Ohsugi; T Yamamoto
Journal:  FEBS Lett       Date:  1996-01-02       Impact factor: 4.124

10.  Downregulation of CD1 marks acquisition of functional maturation of human thymocytes and defines a control point in late stages of human T cell development.

Authors:  P Res; B Blom; T Hori; K Weijer; H Spits
Journal:  J Exp Med       Date:  1997-01-06       Impact factor: 14.307

View more
  15 in total

1.  Agonistic anti-CD148 monoclonal antibody attenuates diabetic nephropathy in mice.

Authors:  Keiko Takahashi; Rachel H Kim; Lejla Pasic; Lilly He; Shinya Nagasaka; Daisuke Katagiri; Tracy May; Akira Shimizu; Raymond C Harris; Raymond L Mernaugh; Takamune Takahashi
Journal:  Am J Physiol Renal Physiol       Date:  2020-01-27

2.  Maintenance of murine platelet homeostasis by the kinase Csk and phosphatase CD148.

Authors:  Jun Mori; Zoltan Nagy; Giada Di Nunzio; Christopher W Smith; Mitchell J Geer; Rashid Al Ghaithi; Johanna P van Geffen; Silke Heising; Luke Boothman; Bibian M E Tullemans; Joao N Correia; Louise Tee; Marijke J E Kuijpers; Paul Harrison; Johan W M Heemskerk; Gavin E Jarvis; Alexander Tarakhovsky; Arthur Weiss; Alexandra Mazharian; Yotis A Senis
Journal:  Blood       Date:  2018-01-04       Impact factor: 22.113

3.  Interplay between the tyrosine kinases Chk and Csk and phosphatase PTPRJ is critical for regulating platelets in mice.

Authors:  Zoltan Nagy; Jun Mori; Vanesa-Sindi Ivanova; Alexandra Mazharian; Yotis A Senis
Journal:  Blood       Date:  2020-04-30       Impact factor: 22.113

Review 4.  Protein tyrosine phosphatases in lymphocyte activation and autoimmunity.

Authors:  Inmoo Rhee; André Veillette
Journal:  Nat Immunol       Date:  2012-04-18       Impact factor: 25.606

Review 5.  Phosphatase regulation of immunoreceptor signaling in T cells, B cells and mast cells.

Authors:  Yacine Bounab; Andrew Getahun; John C Cambier; Marc Daëron
Journal:  Curr Opin Immunol       Date:  2013-05-15       Impact factor: 7.486

6.  Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.

Authors:  Yun-Qing Qiu; Jue Zhou; Xin-Shan Kang; Jian-Zhong Shen-Tu; Lie-Ming Ding; Fen-Lai Tan; Jing Guo; Lan-Juan Li
Journal:  Afr J Tradit Complement Altern Med       Date:  2012-04-02

Review 7.  Regulation of TCR signalling by tyrosine phosphatases: from immune homeostasis to autoimmunity.

Authors:  Stephanie M Stanford; Novella Rapini; Nunzio Bottini
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

8.  The large ectodomains of CD45 and CD148 regulate their segregation from and inhibition of ligated T-cell receptor.

Authors:  Shaun-Paul Cordoba; Kaushik Choudhuri; Hao Zhang; Marcus Bridge; Alp Bugra Basat; Michael L Dustin; P Anton van der Merwe
Journal:  Blood       Date:  2013-04-11       Impact factor: 22.113

9.  Coreceptor scanning by the T cell receptor provides a mechanism for T cell tolerance.

Authors:  Ondrej Stepanek; Arvind S Prabhakar; Celine Osswald; Carolyn G King; Anna Bulek; Dieter Naeher; Marina Beaufils-Hugot; Michael L Abanto; Virginie Galati; Barbara Hausmann; Rosemarie Lang; David K Cole; Eric S Huseby; Andrew K Sewell; Arup K Chakraborty; Ed Palmer
Journal:  Cell       Date:  2014-10-02       Impact factor: 41.582

10.  Regulated expression of PTPRJ/CD148 and an antisense long noncoding RNA in macrophages by proinflammatory stimuli.

Authors:  Richa K Dave; Marcel E Dinger; Megan Andrew; Marjan Askarian-Amiri; David A Hume; Stuart Kellie
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.